scholarly journals Matrix-Assisted Ionization and Tandem Mass Spectrometry Capabilities in Protein Biomarker Characterization—An Initial Study Using the Small Cell Lung Cancer Biomarker Progastrin Releasing Peptide as a Model Compound

2020 ◽  
Author(s):  
Trine Grønhaug Halvorsen ◽  
Maren Christin Stillesby Levernæs ◽  
Cecilie Rosting
Keyword(s):  
Mass Spectrometry ◽  
Lung Cancer ◽  
Tandem Mass Spectrometry ◽  
Small Cell Lung Cancer ◽  
Model Compound ◽  
Initial Study ◽  
Small Cell ◽  
Tandem Mass ◽  
Small Cell Lung ◽  
Lung Cancer Biomarker

scholarly journals Discovery of potential therapeutic targets for non-small cell lung cancer using high-throughput metabolomics analysis based on liquid chromatography coupled with tandem mass spectrometry

RSC Advances ◽  
2019 ◽  
Vol 9 (19) ◽  
pp. 10905-10913 ◽  
Author(s):  
Hong-dan Xu ◽  
Wen Luo ◽  
Yuanlong Lin ◽  
Jiawen Zhang ◽  
Lijuan Zhang ◽  
...  
Keyword(s):  
Mass Spectrometry ◽  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
High Throughput ◽  
Cell Lung Cancer ◽  
Therapeutic Targets ◽  
Small Cell ◽  
Tandem Mass ◽  
Small Cell Lung ◽  
Metabolomics Analysis

High-throughput metabolomics can discover potential therapeutic targets for non-small cell lung cancer.

FLT3 ligand (CDX-301) and stereotactic radiotherapy for advanced non-small cell lung cancer.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. 9618-9618
Author(s):  
Nitin Ohri ◽  
Balazs Halmos ◽  
Madhur Garg ◽  
Jeffrey M Levsky ◽  
Haiying Cheng ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Systemic Therapy ◽  
Advanced Nsclc ◽  
Initial Study ◽  
Small Cell ◽  
Flt3 Ligand ◽  
Small Cell Lung ◽  
Study Therapy

9618 Background: In a murine non-small cell lung cancer (NSCLC) model, we demonstrated synergy between localized radiotherapy and the dendritic cell growth factor fms-like tyrosine kinase 3 (FLT3) ligand. We now present results from a phase II study testing this combination in patients with advanced and treatment-refractory NSCLC. Methods: Advanced NSCLC patients with multifocal active disease after at least one line of systemic therapy and ECOG performance status 0-2 received 5 daily subcutaneous injections of CDX-301 (75 µg/kg) concurrent with stereotactic body radiotherapy (SBRT, 30-54 Gy in 1-5 fractions based on target size and location) directed at a single site of disease. Additional “cycles” of SBRT and CDX-301 could be administered at least four months after the initial study treatment, at the discretion of the treating physicians. The primary endpoint was progression-free survival four months after treatment initiation (PFS4), with a hypothesis that the PFS4 rate would exceed 40%. Secondary endpoints included overall survival (OS) duration, responses on PET (PERCIST criteria) and CT (RECIST criteria), and dose-limiting toxicities (grade ≥3 adverse events within 30 days). Lesions targeted with SBRT were excluded from response assessments. The intended sample size was 29 subjects. Blood samples were obtained for flow cytometry and other analyses of immune activation. Results: Twenty-nine subjects received study therapy between October 2016 and January 2020. Subjects received a median of 3 lines (range: 1-5) of systemic therapy prior to study enrollment, including immune checkpoint inhibitors targeting the PD-1/PD-L1 axis in 26 subjects (90%). At the time of this analysis, the actuarial PFS4 rate is 60%, which exceeds our pre-specified efficacy objective. With a median follow-up duration for living patients of 12 months, the actuarial 12-month OS rate is 55%. Partial response of lesions not targeted with SBRT (“abscopal effect”) was observed in 9 subjects (31%) using PET criteria and in 4 subjects (14%) using CT criteria. Seven subjects (24%) received a second course of SBRT and CDX-301 after initial study therapy. No dose-limiting toxicities have been observed. Only six subjects (21%) have received additional chemotherapy or immunotherapy after study treatment. Conclusions: The combination of CDX-301 and SBRT is well-tolerated and has activity as systemic therapy for advanced NSCLC. Additional studies to maximize the efficacy of this in situ vaccination approach with the addition of an agonist anti-CD40 antibody (CDX-1140) are planned. Clinical trial information: NCT02839265 .

scholarly journals Biomarker testing strategies in non-small cell lung cancer in the real-world setting: analysis of methods in the Prospective Central Lung Cancer Biomarker Registry (LungPath) from the Spanish Society of Pathology (SEAP)

2021 ◽  
pp. jclinpath-2021-208034
Author(s):  
Javier Martín-López ◽  
Federico Rojo ◽  
Antonio Martínez-Pozo ◽  
Teresa Hernández-Iglesias ◽  
David Carcedo ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Real World ◽  
Small Cell ◽  
Small Cell Lung ◽  
The Real ◽  
Biomarker Testing ◽  
Lung Cancer Biomarker

AimsThe aim of this study is to extend the analysis of the Lung Cancer Biomarker Testing Registry (LungPath), by analysing the techniques used in the determination of epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), c-ros oncogene 1 (ROS1) and programmed death ligand-1 (PD-L1) for the diagnostic of patients with advanced non-small-cell lung cancer (NSCLC).MethodsInformation of the technique used for the determination of EGFR, ALK, ROS1 and PD-L1 was recorded from March 2018 to January 2019 from 44 centres, but only 34 centres matched with the 38 centres previously analysed, allowing to analyse the techniques used in 8970 matched determinations of EGFR, ALK, ROS1 and PD-L1. Therefore, a by-centre analysis studied the level of implementation of the techniques in the 44 centres, while a by-determination analysis made it possible to assess the overall frequency of the techniques used on the 9134 matched samples.ResultsBy-centre analysis showed that only 46.5% and 25.6% of the centres used reflex strategies for ALK and ROS1 determination, respectively. By-determination analysis showed that 94.4% of EGFR determinations were performed by PCR, 80.7% of ALK determinations were performed by IHC with clone D5F3, while 55.7% of ROS1 determinations were performed by IHC with clone D4D6. 22C3 were the PD-L1 clone more used (43.5%) followed by SP263 clone (31.1%).ConclusionsThe real-world evidence obtained from LungPath shows the effort of Spanish hospitals in performing biomarker determination in NSCLC with different methodologies despite that next-generation sequencing (NGS) utilisation in the year of the analysis was low. Biomarker determination results could be optimised with the incorporation of sequencing methods such as NGS in pathology departments.

scholarly journals Mass spectrometry-based serum proteomic signature as a potential biomarker for survival in patients with non-small cell lung cancer receiving immunotherapy

2020 ◽  
Vol 9 (4) ◽  
pp. 1015-1028
Author(s):  
Young Kwang Chae ◽  
Won Bin Kim ◽  
Andrew A. Davis ◽  
Lee Chun Park ◽  
Jonathan F. Anker ◽  
...  
Keyword(s):  
Mass Spectrometry ◽  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Potential Biomarker
Sign in / Sign up

Export Citation Format

Share Document